Loading...
Universal Health Services Inc (UHS) is not an optimal buy for a beginner investor with a long-term strategy at this moment. While the company has shown strong financial performance in its latest quarter and has a bullish technical trend, the overbought RSI, insider selling, and mixed analyst sentiment suggest caution. Additionally, there are no strong proprietary trading signals or significant positive catalysts to justify immediate action.
The stock is in a bullish trend with MACD positively expanding and moving averages showing upward momentum (SMA_5 > SMA_20 > SMA_200). However, RSI is at 83.596, indicating the stock is overbought. Key resistance levels are at R1: 236.262 and R2: 247.253, while support levels are at S1: 200.683 and S2: 189.692.

Strong financial performance in Q3 2025 with revenue up 13.43% YoY, net income up 44.16% YoY, and EPS up 54.21% YoY.
Dividend declaration of $0.20 per share, indicating shareholder returns.
Bullish technical indicators with MACD and moving averages.
RSI indicates overbought conditions, suggesting potential short-term price correction.
Insider selling has increased significantly by 291.34% over the last month.
Mixed analyst sentiment with recent price target downgrades and a downgrade to Equal Weight by Wells Fargo.
No significant hedge fund activity and neutral sentiment from institutional investors.
In Q3 2025, Universal Health Services reported revenue of $4.495 billion, up 13.43% YoY. Net income increased to $372.96 million, up 44.16% YoY, and EPS rose to $5.86, up 54.21% YoY. Gross margin remained stable.
Mixed sentiment: Barclays maintains an Overweight rating with a slight price target reduction to $262. TD Cowen lowered its price target to $245 but maintains a Buy rating. Wells Fargo downgraded the stock to Equal Weight with a price target of $235, citing legislative risks and a challenging environment for hospitals in 2026. Guggenheim raised its price target to $274 with a Buy rating.